Literature DB >> 9712824

Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.

A B Hartman1, M M Venkatesan.   

Abstract

Construction of a stable Shigella sonnei vaccine has been complicated by the instability of the virulence phenotype caused by the spontaneous loss of the invasion plasmid. To select a suitable candidate for vaccine construction, 16 S. sonnei strains were screened for stability of the virulence phenotype. A stable strain, S. sonnei Mosely, was selected for further work. pDeltavirG2, a deletion derivative of the virG gene in the sacB suicide vector pCVD442, was used to generate an S. sonnei virG deletion strain, WRSS1, which was invasive in HeLa cells but negative in the Sereny test. WRSS1 was found to be both immunogenic and protective in the guinea pig keratoconjunctivitis model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712824      PMCID: PMC108562          DOI: 10.1128/IAI.66.9.4572-4576.1998

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment.

Authors:  A R HIGGINS; T M FLOYD; M A KADER
Journal:  Am J Trop Med Hyg       Date:  1955-03       Impact factor: 2.345

2.  Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

Authors:  A B Hartman; L L Van de Verg; H H Collins; D B Tang; N O Bendiuk; D N Taylor; C J Powell
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

3.  Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Authors:  K L Kotloff; D A Herrington; T L Hale; J W Newland; L Van De Verg; J P Cogan; P J Snoy; J C Sadoff; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

4.  Vaccine strain Sh. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati).

Authors:  T Meitert; E Pencu; L Ciudin; M Tonciu
Journal:  Arch Roum Pathol Exp Microbiol       Date:  1984 Jul-Dec

5.  Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes.

Authors:  N K Verma; A A Lindberg
Journal:  Vaccine       Date:  1991-01       Impact factor: 3.641

6.  Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin.

Authors:  M L Bernardini; J Mounier; H d'Hauteville; M Coquis-Rondon; P J Sansonetti
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

7.  Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.

Authors:  A B Hartman; C J Powell; C L Schultz; E V Oaks; K H Eckels
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

8.  High frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, streptomycin, chloramphenicol, and tetracycline isolated from patients with shigellosis in northeastern Brazil during the period 1988 to 1993.

Authors:  A A Lima; N L Lima; M C Pinho; E A Barros Juñior; M J Teixeira; M C Martins; R L Guerrant
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  Diarrheal disease during Operation Desert Shield.

Authors:  K C Hyams; A L Bourgeois; B R Merrell; P Rozmajzl; J Escamilla; S A Thornton; G M Wasserman; A Burke; P Echeverria; K Y Green
Journal:  N Engl J Med       Date:  1991-11-14       Impact factor: 91.245

10.  On the serology of Plesiomonas shigelloides.

Authors:  T Shimada; R Sakazaki
Journal:  Jpn J Med Sci Biol       Date:  1978-04
View more
  17 in total

Review 1.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

2.  Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers.

Authors:  Nadav Orr; David E Katz; Jacob Atsmon; Paull Radu; Miri Yavzori; Tamar Halperin; Tamar Sela; Raid Kayouf; Zivit Klein; Ruhama Ambar; Dani Cohen; Marcia K Wolf; Malabi M Venkatesan; Thomas L Hale
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 3.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.

Authors:  M L Bernardini; J Arondel; I Martini; A Aidara; P J Sansonetti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

5.  Vaccines against gastroenteritis, current progress and challenges.

Authors:  Hyesuk Seo; Qiangde Duan; Weiping Zhang
Journal:  Gut Microbes       Date:  2020-06-18

6.  Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine.

Authors:  Malabi M Venkatesan; Antoinette B Hartman; John W Newland; Vessela S Ivanova; Thomas L Hale; Marie McDonough; Joan Butterton
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

7.  Establishment of a Shigella sonnei human challenge model in Thailand.

Authors:  Ladaporn Bodhidatta; Punnee Pitisuttithum; Supat Chamnanchanant; Karen T Chang; Dilara Islam; Valai Bussaratid; Malabi M Venkatesan; Thomas L Hale; Carl J Mason
Journal:  Vaccine       Date:  2012-10-12       Impact factor: 3.641

8.  Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants.

Authors:  Ryan T Ranallo; Robert W Kaminski; Tonia George; Alexis A Kordis; Qing Chen; Kathleen Szabo; Malabi M Venkatesan
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

9.  Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.

Authors:  S Barnoy; K I Jeong; R F Helm; A E Suvarnapunya; R T Ranallo; S Tzipori; M M Venkatesan
Journal:  Vaccine       Date:  2009-11-20       Impact factor: 3.641

10.  Molecular cloning and characterization of genes for Shigella sonnei form I O polysaccharide: proposed biosynthetic pathway and stable expression in a live salmonella vaccine vector.

Authors:  De-Qi Xu; John O Cisar; Nicholas Ambulos; Donald H Burr; Dennis J Kopecko
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.